Home
>
US Stocks
>
TherapeuticsMD, Inc.

TherapeuticsMD, Inc. (TXMD)

$3.86

+0.02

(+0.52%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on TherapeuticsMD, Inc.

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 28.56M → 103.10K (in $), with an average decrease of 42.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -28.96M → 11.05K (in $), with an average increase of 131101.5% per quarter

  • Vs ZTS

    In the last 3 years, TherapeuticsMD Inc has experienced a drawdown of -93.2%, however Zoetis Inc - Class A resisted the overall trend and outperformed by 66.6%

Performance

  • $3.79
    $3.95
    $3.86
    downward going graph

    1.94%

    Downside

    Day's Volatility :4.18%

    Upside

    2.28%

    downward going graph
  • $2.02
    $11.69
    $3.86
    downward going graph

    47.67%

    Downside

    52 Weeks Volatility :82.72%

    Upside

    66.98%

    downward going graph

Returns

PeriodTherapeuticsMD, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-22.18%
0.3%
-6.7%
6 Months
-19.58%
-6.1%
-3.7%
1 Year
-61.13%
-4.8%
-6.3%
3 Years
-93.17%
23.8%
26.9%

Highlights

Market Capitalization
39.4M
Book Value
$3.7
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.88
PE Ratio
2.04
PEG Ratio
-0.73
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
5.13%
Return On Equity TTM
0.0%
Revenue TTM
70.0M
Revenue Per Share TTM
7.75
Quarterly Revenue Growth YOY
-17.7%
Gross Profit TTM
68.1M
EBITDA
11.9M
Diluted Eps TTM
1.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.38
EPS Estimate Next Year
0.35
EPS Estimate Current Quarter
0.06
EPS Estimate Next Quarter
0.06

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for TherapeuticsMD, Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 29.53%

Current $3.86
Target $5.00

Company Financials

FY17Y/Y Change
Revenue
16.8M
↓ 13.32%
Net Income
-76.9M
↓ 14.41%
Net Profit Margin
-458.5%
↑ 5.82%
FY18Y/Y Change
Revenue
16.1M
↓ 4.04%
Net Income
-132.6M
↑ 72.4%
Net Profit Margin
-823.74%
↓ 365.24%
FY19Y/Y Change
Revenue
49.6M
↑ 208.38%
Net Income
-176.1M
↑ 32.82%
Net Profit Margin
-354.8%
↑ 468.94%
FY20Y/Y Change
Revenue
64.9M
↑ 30.67%
Net Income
-183.5M
↑ 4.19%
Net Profit Margin
-282.9%
↑ 71.9%
FY21Y/Y Change
Revenue
87.0M
↑ 34.03%
Net Income
-172.4M
↓ 6.05%
Net Profit Margin
-198.29%
↑ 84.61%
FY22Y/Y Change
Revenue
70.0M
↓ 19.54%
Net Income
112.0M
↓ 164.96%
Net Profit Margin
160.08%
↑ 358.37%
Q4 FY21Q/Q Change
Revenue
18.7M
↓ 26.48%
Net Income
-43.0M
↓ 9.41%
Net Profit Margin
-230.0%
↓ 43.35%
Q1 FY22Q/Q Change
Revenue
19.3M
↑ 3.51%
Net Income
-49.0M
↑ 14.11%
Net Profit Margin
-253.56%
↓ 23.56%
Q2 FY22Q/Q Change
Revenue
28.6M
↑ 47.73%
Net Income
112.3M
↓ 329.05%
Net Profit Margin
393.13%
↑ 646.69%
Q3 FY22Q/Q Change
Revenue
20.9M
↓ 26.76%
Net Income
-29.0M
↓ 125.8%
Net Profit Margin
-138.48%
↓ 531.61%
Q4 FY22Q/Q Change
Revenue
103.1K
↓ 99.51%
Net Income
11.1K
↓ 100.04%
Net Profit Margin
10.72%
↑ 149.2%
Q1 FY23Q/Q Change
Revenue
103.1K
↑ 0.0%
Net Income
11.1K
↑ 0.0%
Net Profit Margin
10.72%
↑ 0.0%
FY17Y/Y Change
Total Assets
143.2M
↑ 0.53%
Total Liabilities
13.3M
↓ 11.09%
FY18Y/Y Change
Total Assets
212.0M
↑ 48.0%
Total Liabilities
114.5M
↑ 759.23%
FY19Y/Y Change
Total Assets
266.0M
↑ 25.47%
Total Liabilities
256.8M
↑ 124.34%
FY20Y/Y Change
Total Assets
181.6M
↓ 31.72%
Total Liabilities
305.6M
↑ 19.01%
FY21Y/Y Change
Total Assets
169.5M
↓ 6.68%
Total Liabilities
263.1M
↓ 13.91%
FY22Y/Y Change
Total Assets
90.5M
↓ 46.62%
Total Liabilities
55.3M
↓ 78.98%
Q4 FY21Q/Q Change
Total Assets
169.5M
↓ 19.16%
Total Liabilities
263.1M
↓ 1.46%
Q1 FY22Q/Q Change
Total Assets
133.4M
↓ 21.3%
Total Liabilities
274.0M
↑ 4.13%
Q2 FY22Q/Q Change
Total Assets
146.2M
↑ 9.61%
Total Liabilities
172.3M
↓ 37.12%
Q3 FY22Q/Q Change
Total Assets
133.9M
↓ 8.41%
Total Liabilities
182.2M
↑ 5.75%
Q4 FY22Q/Q Change
Total Assets
809.0K
↓ 99.4%
Total Liabilities
49.2K
↓ 99.97%
Q1 FY23Q/Q Change
Total Assets
809.0K
↑ 0.0%
Total Liabilities
49.2K
↑ 0.0%
FY17Y/Y Change
Operating Cash Flow
-76.2M
↑ 10.14%
Investing Cash Flow
-827.1K
↓ 34.12%
Financing Cash Flow
72.6M
↓ 47.11%
FY18Y/Y Change
Operating Cash Flow
-106.8M
↑ 40.25%
Investing Cash Flow
-21.5M
↑ 2499.16%
Financing Cash Flow
162.8M
↑ 124.27%
FY19Y/Y Change
Operating Cash Flow
-165.7M
↑ 55.13%
Investing Cash Flow
-23.9M
↑ 11.23%
Financing Cash Flow
188.8M
↑ 16.0%
FY20Y/Y Change
Operating Cash Flow
-159.5M
↓ 3.76%
Investing Cash Flow
-1.6M
↓ 93.32%
Financing Cash Flow
80.7M
↓ 57.25%
FY21Y/Y Change
Operating Cash Flow
-142.7M
↓ 10.52%
Investing Cash Flow
-2.2M
↑ 39.12%
Financing Cash Flow
129.6M
↑ 60.49%
Q4 FY21Q/Q Change
Operating Cash Flow
-39.6M
↑ 3.49%
Investing Cash Flow
-1.5M
↑ 731.87%
Financing Cash Flow
1.4M
↓ 95.75%
Q1 FY22Q/Q Change
Operating Cash Flow
-29.5M
↓ 25.36%
Investing Cash Flow
-212.0K
↓ 86.0%
Financing Cash Flow
-5.0M
↓ 469.55%
Q2 FY22Q/Q Change
Operating Cash Flow
-15.4M
↓ 47.83%
Investing Cash Flow
142.6M
↓ 67344.81%
Financing Cash Flow
-120.0M
↑ 2299.72%
Q3 FY22Q/Q Change
Operating Cash Flow
-18.9M
↑ 22.83%
Investing Cash Flow
-31.0K
↓ 100.02%
Financing Cash Flow
19.7M
↓ 116.44%

Technicals Summary

Sell

Neutral

Buy

TherapeuticsMD, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
TherapeuticsMD, Inc.
TherapeuticsMD, Inc.
12.87%
-19.58%
-61.13%
-93.17%
-98.8%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-12.02%
-24.82%
-2.11%
-26.64%
-2.82%
Zoetis Inc.
Zoetis Inc.
-8.25%
11.42%
-3.62%
18.19%
98.12%
Viatris Inc.
Viatris Inc.
-2.72%
-18.56%
-25.79%
-44.28%
-44.28%
Catalent, Inc.
Catalent, Inc.
-25.94%
-21.32%
-63.98%
-52.24%
-4.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
TherapeuticsMD, Inc.
TherapeuticsMD, Inc.
2.04
2.04
-0.73
-0.38
0.0
0.05
0.0
3.7
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
148.68
148.68
1.87
1.93
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
37.47
37.47
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.82
5.82
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.21
16.21
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
TherapeuticsMD, Inc.
TherapeuticsMD, Inc.
Buy
$39.4M
-98.8%
2.04
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$9.0B
-2.82%
148.68
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$76.4B
98.12%
37.47
25.59%
Viatris Inc.
Viatris Inc.
Hold
$10.9B
-44.28%
5.82
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.7B
-4.13%
16.21
8.62%

Institutional Holdings

  • Rubric Capital Management LP

    17.65%

  • Vanguard Group Inc

    3.87%

  • Tejara Capital Ltd

    3.19%

  • Clearline Capital LP

    2.35%

  • Morgan Stanley - Brokerage Accounts

    1.34%

  • Sixth Street Partners Management Company, L.P.

    1.25%

Company Information

TherapeuticsMD Inc. is an inventive pharmaceutical company that focuses exclusively on healthcare products for women and informs on women’s health problems. The company is dedicated to producing advanced therapeutic products related to family planning, reproductive health, and menopause management with the view to addressing the unique challenges that women face in the different phases of their lives. Founded in 2008 by Brian Bernick and Robert Finizio, the company is headquartered in Boca Raton, Florida. TherapeuticsMD delivers bio-identical hormones in various forms and administration methods using its homegrown SYMBODA technology. It makes fetal vitamins and other nutritional supplements under its vitaMedMD brand and exclusively prescribed prenatal vitamins through BocaGreenMD. These products are produced by a third-party manufacturer- Lang Pharma Nutrition. The company's solutions include long-lasting contraceptives, pharmaceutical products for hormone therapy, and patient-controlled contraceptives. Aside from developing prescription-only hormone therapy products for women, TherapeuticsMD is designing products to address menopausal vasomotor symptoms and dyspareunia. Currently, the firm markets and sells its products through a direct national sales force of about 50 full-time professionals that target health care providers in the OB/GYN sector. Medical professionals may also be able to provide patients with an alternative that meets their individual nutritional and financial needs about co-pays and costs of care and saves them money compared with competing products.. Currently TherapeuticsMD Inc has a market cap of $0.04 Billion. It has a P.E ratio of 0.25. The shares of TherapeuticsMD Inc are trading at $3.86. .

Organization
TherapeuticsMD, Inc.
Employees
1
CEO
Governor Thomas G. Thompson
Industry
Health Technology

Discover More

FAQs